Loading…
Skye Bioscience, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.8% over 5Y.
today you would have $7.95▼ -99.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 11 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $6.00 | $22.64 | $21.76 | $32.00 | $104.00 | $80.00 | $262.00 | $800.00 | $304.00 | $604.00 | $1,400.00 | |
| P/B | 4.4x | 1.3x | 1.3x | — | — | 4.4x | 31.1x | 43.8x | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AIMAIM ImmunoTech Inc. | $0.26 | — | 1.0x | — | -2382.30% | $7.87M |
| TRIBTrinity Biotech PLC | $9.68 | — | — | — | — | $7.87M |
| ICCMIceCure Medical Ltd. | $2.30 | — | 0.7x | — | -228.31% | $7.88M |
| ITOCiTonic Holdings Ltd | $0.32 |
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Company description provided by Yahoo Finance.
| — |
| EPS | -$11.28 | -$5.84 | -$42.96 | -$70.16 | -$40.00 | -$60.00 | -$100.00 | -$320.00 | -$220.00 | -$340.00 | -$580.00 |
| ROE | -145.33% | -279.29% | -38.98% | — | — | -145.33% | -1455.39% | 191.92% | — | — | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.9x |
| — |
| -71.25% |
| $7.83M |
| ENSCEnsysce Biosciences, Inc. | $0.40 | — | — | — | -1295.09% | $7.78M |
| AIDX20/20 Biolabs, Inc. | $0.62 | — | 4.7x | — | -331.22% | $7.97M |